Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Tirzepatide (Dual GIP/GLP-1 Agonist) Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors: GLP-1 effects same appetite suppression and insulin sensitivity as semaglutide GIP receptor activation enhances fat metabolism and insulin secretion through a complementary pathway Synergistic signaling the dual mechanism produces greater metabolic effects than either pathway alone This dual agonism is why Tirzepatide has shown superior weight loss in head-to-head trials
Nigeria Glutathione Market Size and Forecast, by Product Form (2025-2032) 8.4.3.3
Peptides cannot: Reattach a completely torn tendon
3 Follow-up data from the SURMOUNT-4 trial shows the weight loss is maintained at 88 weeks with continued use
